Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Hepatic tristetraprolin promotes insulin resistance through RNA destabilization of FGF21
Konrad T. Sawicki, … , Perry J. Blackshear, Hossein Ardehali
Konrad T. Sawicki, … , Perry J. Blackshear, Hossein Ardehali
Published July 12, 2018
Citation Information: JCI Insight. 2018;3(13):e95948. https://doi.org/10.1172/jci.insight.95948.
View: Text | PDF
Research Article Metabolism

Hepatic tristetraprolin promotes insulin resistance through RNA destabilization of FGF21

  • Text
  • PDF
Abstract

The role of posttranscriptional metabolic gene regulatory programs in diabetes is not well understood. Here, we show that the RNA-binding protein tristetraprolin (TTP) is reduced in the livers of diabetic mice and humans and is transcriptionally induced in response to insulin treatment in murine livers in vitro and in vivo. Liver-specific Ttp-KO (lsTtp-KO) mice challenged with high-fat diet (HFD) have improved glucose tolerance and peripheral insulin sensitivity compared with littermate controls. Analysis of secreted hepatic factors demonstrated that fibroblast growth factor 21 (FGF21) is posttranscriptionally repressed by TTP. Consistent with increased FGF21, lsTtp-KO mice fed HFD have increased brown fat activation, peripheral tissue glucose uptake, and adiponectin production compared with littermate controls. Downregulation of hepatic Fgf21 via an adeno-associated virus–driven shRNA in mice fed HFD reverses the insulin-sensitizing effects of hepatic Ttp deletion. Thus, hepatic TTP posttranscriptionally regulates systemic insulin sensitivity in diabetes through liver-derived FGF21.

Authors

Konrad T. Sawicki, Hsiang-Chun Chang, Jason S. Shapiro, Marina Bayeva, Adam De Jesus, Brian N. Finck, Jason A. Wertheim, Perry J. Blackshear, Hossein Ardehali

×

Figure 1

Hepatic TTP is induced by insulin and reduced in diet-induced and genetic murine models of obesity and human diabetics.

Options: View larger image (or click on image) Download as PowerPoint
Hepatic TTP is induced by insulin and reduced in diet-induced and geneti...
(A) Hepatic Ttp mRNA expression is reduced in C57BL/6 mice after 8 weeks of high-fat diet compared with normal chow (n = 4). (B) Hepatic Ttp mRNA expression is reduced in 8-week-old db/db mice compared with db/+ mice (n = 4). (C) Hepatic TTP mRNA expression is reduced in diabetic humans compared with nondiabetic humans (n = 6). (D) Hepatic TTP protein expression is induced in C57BL/6 mice after 4 hours of i.p. insulin injection compared with control saline injection (n = 3). Densitometry analysis is provided next to the Western blot. (E) Hepatic Ttp mRNA expression is induced in C57BL/6 mice after 4 hours of i.p. insulin injection compared with control saline injection (n = 3). (F) Hepatic protein levels of TTP are induced in 8-week-old db/+ mice 4 hours after i.p. injection of insulin (0.0075 U/g body weight) compared with saline injection but not in db/db mice (n = 3). Densitometry analysis is provided next to the Western blot. Data are presented as mean ± SEM. *P < 0.05 by 1-way ANOVA with post hoc Fisher’s least significant difference (LSD) test.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts